Abpro Stock (NASDAQ:ABP)

Revenue Financials Chart

Previous Close

$1.15

52W Range

$0.95 - $13.00

50D Avg

$2.15

200D Avg

$8.88

Market Cap

$58.03M

Avg Vol (3M)

$747.55K

Beta

Div Yield

ABP Company Profile

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 09, 2022

Website

ABP Performance

ABP Financial Summary

	Dec 23	Dec 22	Dec 17
Revenue	$122.00K	$2.03M	$2.20M
Operating Income	$-11.75M	$-16.68M	$-12.36M
Net Income	$-11.71M	$-17.21M	$-12.36M
EBITDA	$-10.89M	$-15.78M	$-12.17M
Basic EPS	$-0.23	$-0.34	-
Diluted EPS	$-0.23	$-0.34	-

Fiscal year ends in Dec 23 | Currency in USD